QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Nordic managed entry agreements (MEAs): shared goals, different pathways 💡
Managed Entry Agreements (MEAs) are important tools for reimbursement across Sweden, Norway, Denmark, and Finland – especially in areas such as oncology, rare diseases and precision medicine. While their use is growing, the pathways and requirements differ substantially between countries.
From what we’re seeing at Quantify:
■ The road to MEAs differs in each country, for instance:
➡️ In Sweden and Finland, for outpatient medicines, companies may propose MEAs during the reimbursement […]
ISPOR spotlight: Nordic RWE in Myelofibrosis (MF), T2D, and mIDH Glioma
Next week at ISPOR Europe, Quantify is proud to present three poster studies co-authored with our pharma partners; each grounded in the power of Nordic real-world data.
📍 If you’re attending, here’s where to find us:
📅 Tuesday, Nov 11
✉️ Poster 1: Mapping of Treatment Patterns and Transfusion Status in Danish and Swedish Myelofibrosis (MF) Patients – Click here
• Session: Poster Session 3
• Time: 10:30–13:30 GMT
• Board: #2100
📅 Wednesday, Nov 12
✉️Poster 2: Real-World […]
📍Next stop: Glasgow
A late Friday post as we wrap up the week — We’re making our way to ISPOR Europe this weekend, kicking off Monday, 10 November.
You’ll find us alongside our colleagues from IGES Pharma and IGES MedTech —fellow members of the athagoras Group.
Wishing everyone a restful weekend before a great week of […]
Nordic collaboration for health data: more than a dream
Last week, Emilie Toresson Grip, Ville Perälä and Katja Nolvi attended the Nordic Health Data Summit – A VALO & FinHITS Forum in Helsinki, where one thing was clear:
– The Nordics can—and must—collaborate on health data.
The first phase of the VALO project, initiated by The Nordic Council of Ministers, is concluding. Phase II is now launching, continuing the work of preparing the region for European Health Data Space (EHDS) implementation.
As Emilie Toresson Grip noted in […]